ICOSLG and systemic lupus erythematosus: However, the list of “T cell” therapeutics for autoimmune disease is brief, and many of them [i.e., secukinumab, ixekizumab, broalumab, ustekinumab, iberdomide, AMG 570 targeting ICOS-L (NCT04058028)] have either yet to be proven efficacious in the treatment of SLE, are still in early clinical trials, or broadly target the functions of other immune cells (114–116).